Psyence BioMed Secures Exclusive U.S. Ibogaine License in $1.3M Deal
Event summary
- Psyence BioMed's Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), has signed a binding term sheet with PsyLabs for an exclusive U.S. license to develop, manufacture, and distribute pharmaceutical-grade ibogaine.
- The deal includes up to $1.3M in milestone payments, a low single-digit royalty on net sales, and a margin-sharing arrangement on resales.
- The definitive agreement must be finalized by November 30, 2026, or the term sheet will lapse.
- TIRC will pay an annual exclusivity fee starting on the first anniversary of the first FDA approval, creditable against royalties.
- PsyLabs retains all rights outside the United States.
The big picture
This exclusive license deal underscores Psyence BioMed's strategic push into the U.S. market for ibogaine-based therapeutics, a compound with significant potential in addressing unmet mental health needs. The agreement with PsyLabs, a significant shareholder and partner, highlights the company's vertically integrated approach to neuroplastogen-based treatments. The deal size and exclusivity terms suggest a high-stakes bet on the regulatory and commercial viability of ibogaine in the U.S.
What we're watching
- Regulatory Milestones
- The pace at which TIRC advances through manufacturing, nonclinical, and regulatory work will determine the timeline for clinical investigations.
- Execution Risk
- Whether TIRC can meet minimum performance thresholds to maintain exclusivity under the definitive agreement.
- Market Dynamics
- How the exclusive U.S. license positions TIRC in the competitive landscape of ibogaine development and distribution.
Related topics